<DOC>
	<DOCNO>NCT00373373</DOCNO>
	<brief_summary>The primary purpose study determine , whether addition Sorafenib standard chemotherapy elderly patient newly diagnose AML improve treatment result ( event free survival ) .</brief_summary>
	<brief_title>Efficacy Sorafenib Added Standard Primary Therapy Elderly Patients With Newly Diagnosed AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients newly diagnose AML ( except APL ) accord FAB WHO classification , include AML evolve MDS hematologic disease AML previous cytotoxic therapy radiation ( secondary AML ) Bone marrow aspirate biopsy must contain &gt; = 20 % blast nucleate cell , exception AML FAB M6 , &gt; = 30 % nonerythroid cell must leukemic blast Age &gt; = 61 year Informed consent , personally sign date participate study Male patient enrol trial must use adequate barrier birth control measure course Sorafenib treatment least 3 month last administration Sorafenib Central nervous system manifestation AML Cardiac Disease : Heart failure NYHA III° IV° ; active coronary artery disease ( MI 6 month prior study entry permit ) ; serious cardiac ventricular arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Chronically impaired renal function ( creatinin clearance &lt; 30 ml/min ) Chronic pulmonary disease relevant hypoxia Inadequate liver function ( ALT AST &gt; = 2.5 x ULN ) Total bilirubin &gt; = 1.5 x ULN Resting blood pressure ( BP ) consistently high systolic 160 mmHg and/or diastolic 95 mmHg Any severe concomitant condition make undesirable patient participate study could jeopardise compliance protocol Uncontrolled active infection Concurrent malignancy AML Previous treatment AML except hydroxyurea 2 day &lt; = 100 mg/m²/d cytarabine Known HIV and/or hepatitis C infection Evidence history CNS disease , include primary metastatic brain tumor , seizure disorder Thrombotic embolic event cerebrovascular accident pulmonary embolism within 1 year study entry Evidence history severe nonleukemia associate bleed diathesis coagulopathy History organ allograft Concomitant treatment kinase inhibitor , angiogenesis inhibitor Myelotarg Patients major surgery , open biopsy significant traumatic injury within 4 week start first dose Serious , nonhealing wound , ulcer bone fracture Allergy study medication excipients study medication Investigational drug therapy outside trial within 4 week study entry Patients eligible standard chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Flt3</keyword>
	<keyword>AML</keyword>
	<keyword>Kinase Inhibitor</keyword>
</DOC>